These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36428582)

  • 21. Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
    Steininger J; Gellrich FF; Schulz A; Westphal D; Beissert S; Meier F
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives.
    Dugan MM; Perez MC; Karapetyan L; Zager JS
    Cancer Manag Res; 2024; 16():933-939. PubMed ID: 39099762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
    White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
    Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
    Okuma T; Furudate S; Kambayashi Y; Hashimoto A; Aiba S; Fujimura T
    J Dermatol; 2021 Sep; 48(9):1419-1422. PubMed ID: 34002878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
    BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
    Dixon-Douglas JR; Patel RP; Somasundram PM; McArthur GA
    Curr Oncol Rep; 2022 Aug; 24(8):1071-1079. PubMed ID: 35366166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials.
    Li B; Jin J; Guo D; Tao Z; Hu X
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
    van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
    JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM; Dumas L; Larkin J
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
    Deken MA; Gadiot J; Jordanova ES; Lacroix R; van Gool M; Kroon P; Pineda C; Geukes Foppen MH; Scolyer R; Song JY; Verbrugge I; Hoeller C; Dummer R; Haanen JB; Long GV; Blank CU
    Oncoimmunology; 2016; 5(12):e1238557. PubMed ID: 28123875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
    Stagno A; Vari S; Annovazzi A; Anelli V; Russillo M; Cognetti F; Ferraresi V
    Front Oncol; 2021; 11():645008. PubMed ID: 34136385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy.
    Myrdal CN; Sundararajan S
    Case Rep Oncol Med; 2020; 2020():4392562. PubMed ID: 32670650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.
    Lau PKH; Cullinane C; Jackson S; Walker R; Smith LK; Slater A; Kirby L; Patel RP; von Scheidt B; Slaney CY; McArthur GA; Sheppard KE
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.